The Australian share market, as represented by the S&P/ASX 200 Index (ASX: XJO), is showing positive momentum this week. The index has seen a notable increase of 0.8% since yesterday morning, and year-to-date, it’s currently tracking 1.86% higher.
While the broader market is on an upward trend, several individual ASX 200 stocks are poised to significantly outperform the index this year. Analysts are particularly optimistic about the prospects of three specific companies, with projections suggesting potential upside ranging from an impressive 50% to 60% for each.
Aristocrat Leisure Ltd (ASX: ALL)
Aristocrat Leisure is a prominent Australian-based gaming technology company with a substantial global footprint. The company holds licenses in approximately 340 gaming jurisdictions across more than 100 countries, underscoring its extensive reach in the international gaming market.
As of Tuesday afternoon, Aristocrat’s shares were trading in positive territory, up 0.58% to $52.31. Despite a year-to-date decline of 8.61% and a 29.25% drop over the past year, analysts remain confident in the company’s future growth potential. The gaming giant has faced headwinds, including the impact of a strengthening Australian dollar, which has affected its financial performance.
However, market watchers believe that Aristocrat is well-positioned to reverse its recent share price performance over the next 12 months. Current data reveals a consensus ‘buy’ rating among analysts, with a maximum target price of $82.20 per share. This suggests a potential upside of approximately 56.98% from the current trading price.
CAR Group Ltd (ASX: CAR)
CAR Group Ltd is a global digital marketplace business with its headquarters firmly rooted in Australia. The company is renowned for operating leading automotive websites such as carsales, Encar, and Trader Interactive, connecting buyers and sellers in the automotive industry worldwide.
The company recently announced robust revenue and earnings growth in its FY26 half-year results, while also reaffirming its full-year financial guidance. Despite this strong operational performance, a broader market sell-off and general weakness in the automotive sector have exerted downward pressure on the stock during the initial month of 2026.
At the time of writing, CAR Group’s shares were trading 1.93% higher at $27.43 each. However, year-to-date, the stock has experienced a decline of 11.14%, and it is currently trading 28.49% lower than it was at the same point last year.
Despite these recent challenges, analysts are expressing significant optimism regarding CAR Group’s share price trajectory over the coming 12 months. The highest analyst target price for the stock is $42.20, indicating a potential upside of approximately 53.79% from its current valuation.
Ebos Group Ltd (ASX: EBO)
Ebos Group stands as the largest pharmaceutical wholesaler and distributor across Australia, New Zealand, and Southeast Asia. The company plays a critical role in the healthcare supply chain, providing essential pharmaceutical and wellness products to a diverse range of clients. These include community pharmacies, public and private hospitals, day surgeries, general practices, aged care facilities, and specialist clinics.
Ebos Group is a relatively new entrant to the ASX 200 index, with its shares being admitted to the index on September 22nd. In the preceding August, the healthcare stock experienced a significant downturn, crashing by 14% to a four-year low. This decline was attributed to investor apprehension following a disappointing FY25 results announcement.
Since its inclusion in the ASX 200 in September, Ebos’s shares have continued to face downward pressure, tumbling by an additional 14%. Currently, the shares are trading 0.37% higher at $21.98 per piece.
However, a growing number of analysts believe that the stock is currently oversold and significantly undervalued. The analyst sentiment reflects this view, with five out of nine analysts recommending a ‘buy’ or ‘strong buy’ rating on Ebos shares. An additional two analysts have a ‘hold’ rating, while two recommend a ‘sell’. The highest analyst target price is set at $34.82, suggesting a substantial potential upside of 58.34% at the current trading levels.
